How Often Do You See Neuroleptic Malignant Syndrome?
Question by Olga: How often do you see Neuroleptic Malignant Syndrome?
I’ve been working as a Psychiatric RN for a number of years now and I have never seen a single case of NMS.
How often do we still see NMS in current times?
Best answer:
Answer by rb43081
It is certainly believed that the risk/incidence of NMS (and all acute extrapyramidal syndromes) should be decreasing with the increased use of newer drugs. On the other hand, ALL drugs are being used more often, perhaps for longer periods of time and possibly, in patients of greater risk (older, for example).
Take a look at this:
Mov Disord. 2006 May;21(5):589-98.
Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?
Tarsy D, Baldessarini RJ.
Department of Neurology, Harvard Medical School, and Beth Israel-Deaconess Medical Center, Boston, Massachusetts 02215, USA. [email protected]
Abstract
Second-generation antipsychotic drugs (APDs), including aripiprazole, clozapine, olanzapine, risperidone, quetiapine, and ziprasidone dominate outpatient and inpatient clinical practice, having largely displaced the older neuroleptics. Modern APDs have relatively low risk for acute extrapyramidal syndromes characteristic of older neuroleptics, particularly acute dystonia and Parkinsonism, with variable risks of akathisia and the rare neuroleptic malignant syndrome. Anticipated reduction in risk of tardive dyskinesia (TD) is less well documented. Nearly 50 years after initial reports on TD, it is appropriate to reexamine the epidemiology of this potentially severe late adverse effect of long-term APD treatment in light of current research and practice. We compared recent estimates of incidence and prevalence of TD identified with some modern APDs to the epidemiology of TD in the earlier neuroleptic era. Such comparisons are confounded by complex modern APD regimens, uncommon exposure limited to a single modern APD, effects of previous exposure to typical neuroleptics, and neurological assessments that are rarely prospective or systematic. Available evidence suggests that the risk of TD may be declining, but longitudinal studies of patients never treated with traditional neuroleptics and exposed to only a single modern APD are required to quantify TD risks with specific drugs. Long-term use of APDs should continue to be based on research-supported indications, with regular specific examination for emerging TD.
=====================
Rex, a physician, in the midwest
What do you think? Answer below!
Drug Treatment Norfolk County Call 857-362-7482 For Help Now MA – Drug Treatment Norfolk County Call 857-362-7482 For Help Now For Help Now MA. If you are looking for Drug Detox Norfolk County MA, Drug Treatment Norfolk County MA, Drug Rehab Center Norfolk County MA, Alcohol Rehab Norfolk County MA, Drug and Alcohol Treatment Norfolk County MA, Drug Intervention Norfolk County MA, Alcohol Treatment Norfolk County MA, Alcohol Detox Norfolk County MA, then contact us. Drug Detox Norfolk County MA offers trained counselors and holistic programs for long term physical, physiological, behavioral, social and spiritual recovery no matter if you or your loved one is suffering from drug, alcohol or cocaine addiction alcohol and detox programs.
Then and now: Alice MacCorkle and Greg Burns, still laughing after all these years
Filed under: Massachusetts Drug Treatment Centers
He then worked as a child/adolescent psychotherapist, and later became the drug and alcohol treatment coordinator at a locked psychiatric facility in San Jose. He's now a professional and executive … During her senior year at M-A, she was head …
Read more on InMenlo
Dr. David Glass' research kept many kids walking
Filed under: Massachusetts Drug Treatment Centers
“Part of our courtship was going on 'bleeding trips,' driving around Massachusetts, taking blood from three generations of the families of arthritis patients,” she said. After Dr. Glass was recruited to … Because malfunctions in many different genes …
Read more on Cincinnati.com
FDA approves pump for heart failure patients awaiting heart transplant
Filed under: Massachusetts Drug Treatment Centers
“For patients awaiting a donor heart, the HeartWare System provides a new treatment option,” said Christy Foreman, director of the Office of Device Evaluation in FDA's Center for Devices and Radiological Health. Other available LVADs require components …
Read more on FDA.gov